Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer drugs, improving their targeting and uptake into cells. Here, we examine the appropriateness of different sized AuNPs as components of platinum based drugdelivery systems, investigating their controlled synthesis, reproducibility, consistency of drug loading and stability. The active component of cisplatin was tethered to 25, 55 and 90 nm AuNPs; with the nanoparticles being almost spherical in nature and demonstrating good batch-to-batch reproducibility (24.37 ± 0.62 nm, 55.2 ± 1.75 nm and 89.1 ± 2.32 nm). The size distribution of 25 nm AuNPs has been significantly improved, compared with a previous method which produces polydispersed nanoparticles. Attachment of platinum to the AuNP surface through a polyethylene glycol (PEG) linker exhibits an increase in drug loading with increasing particle size: 25 nm (815 ± 106 drug molecules per AuNP); 55 nm (14,216 ± 880); and 90 nm (54,487 ± 15,996). The stability of the naked, PEGylated and platinum conjugated nanoparticles has been examined over time under various conditions. When stored at 4 ºC there is minimal variation in diameter for all three AuNP sizes; variation after 28 days for the 25 nm AuNPs was 2.4%; 55 nm, 3.3%; and 90 nm, 3.6%. The 25 nm AuNPs also demonstrate minimal changes in UV-visible absorbance over the same time period.
Introduction
Cisplatin, cis-diamminedichloridoplatinum (II) , is the leading metallodrug used in the systemic treatment of solid tumors. 1 Its clinical use is limited by severe toxic side effects, attributed to the indiscriminate accumulation of the drug in both normal and cancerous tissue, its non-specific interactions with extra-and intracellular proteins, and drug resistance, both intrinsic and acquired. 2 The focus of drug development is now being directed towards delivery vehicles which can overcome these limitations, and can specifically target cancerous cells.
Due to the unique disorganised vasculature of cancer cells with numerous pores, coupled with compromised lymphatic drainage, nanoparticles can passively target solid tumours, leading to an enhanced permeability and retention (EPR) effect. 3 This EPR effect can be utilised by nanotechnology-based drug delivery as it enhances the accumulation of the drug in tumours and minimises uptake by healthy cells. 4 For optimal efficacy, nanoparticle-based systems must take into consideration the gaps in the tumour vasculature endothelium, which can range from 100 nm to 2 µm, 5 and nanoparticle clearance, which varies with nanoparticle size. 6 Gold nanoparticles (AuNPs) are particularly attractive as chemotherapy delivery vehicles as they are non-toxic, biocompatible and easily synthesised. [7] [8] [9] [10] [11] [12] In addition to size, their cellular uptake is dependent upon shape and surface charge. [13] [14] [15] There are two important considerations in the endocytosis of gold nanoparticles; the binding energy between the ligand and receptor, and the free energy required to drive the nanoparticles into the cell. 13 Uptake is limited for either extremely small or large nanoparticles, with the optimal diameter reported as between 40-60 nm. 6, [13] [14] [15] We have previously shown that tethering the active component of the platinum
anticancer drug oxaliplatin to a 20 nm gold nanoparticle via a thiolated PEG linker increases cytotoxicity, compared with oxaliplatin alone, and demonstrates nuclear penetration. 16 Gold nanoparticles and gold nanorods have also been used as platforms for the delivery of platinum(IV) prodrugs, demonstrating enhanced cellular uptake and superior cytotoxicity compared with cisplatin. 17, 18 Cisplatin has been loaded onto gold nanoparticles of the form Au-Au 2 S and Au-Fe 3 O 4 for photodynamic thermal therapy and magnetically controlled delivery, respectively. 19, 20 Demonstrating that drugs can be tethered to nanoparticles, and that these conjugates improve drug uptake and/or activity, is just the first step in the long and complex drug approval process. There are a number of other crucial factors to consider which, to our knowledge, for this type of platinum based drug-delivery
vehicle have yet to be investigated. Constructing a drug-nanoparticle conjugate with reproducible size and shape which demonstrates consistent drug loading, is important for its ability to be administered for therapeutic use; i.e., it ensures the concentration of delivered drug remains constant. Stability, both during manufacture and storage, must also be established to guarantee that the performance is unaffected and the system remains safe.
In this paper we report the construction of platinum tethered gold nanoparticle conjugates using the active component of the common anticancer drug cisplatin ( Figure 1 ). This has been achieved for small, medium and large AuNPs (25, 55 and 90 nm, respectively), where the synthesis shows good reproducibility and monodispersity. The drug-nanoparticle conjugates have been characterised using UV-visible spectrometry, dynamic light scattering (DLS), and atomic force microscopy (AFM). The platinum drug was tethered to the AuNPs using a polyethylene glycol (PEG) linker, and drug loading was determined using inductively coupled plasma-mass spectrometry (ICP-MS). Finally, we have determined the effect of platinum drug concentration on the stability of the AuNPs during synthesis, as well as examining the growth of naked, PEGylated and drug conjugated nanoparticles under various conditions.
Results and Discussion

Construction of drug-nanoparticle conjugate
The size of a gold nanoparticle can be controlled via the route of synthesis; the BrustSchiffrin synthesis involves an organic two-phase reduction and typically yields AuNPs 5-6 nm in diameter. 21 The Turkevich-Frens method of reducing a gold salt with sodium citrate has been reported to produce nanoparticles of 9-120 nm, 22 with larger nanoparticles in the region of 50-200 nm being produced via the reduction of HAuCl 4 with hydroquinone in an aqueous solution containing seeds. 23 Our aim was to synthesise small, medium and large AuNPs (25, 55 and 90 nm, respectively) which demonstrate good reproducibility. This is a necessity in the construction of a drug-delivery vehicle to ensure a consistent drug payload is being administered and that the response, whether in vitro or in vivo, can be accurately predicted.
The nanoparticles synthesised in this study have been produced from the reduction of sodium tetrachloroaurate(III) by tribasic sodium citrate, where the size of the nanoparticles is determined primarily by the pH of the solution, which in turn is controlled by the concentration of sodium citrate. 24 In this method sodium citrate functions as both the nucleating and growth agent, 7 as well as distributing a negative charge on the nanoparticle surface to minimise aggregation. A higher citrate concentration allows for the stabilisation of smaller particles, while at lower 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 concentrations, the coverage is incomplete and a coarsening process leads to aggregation, producing larger particles. 22 These larger nanoparticles have been shown to sometimes be polydispersed and yield low particle concentrations. 25 Nanoparticles, 25 nm in diameter, were initially synthesised via the established citrate reduction method. 7, 26 This, however, produced a bimodal size distribution curve, as determined by dynamic light scattering (DLS), with peaks at 3.4 and 45.4 nm ( Figure 2 ). This is problematic as it is only with monodispersed systems that a reliable and precise dosage of drugs can be assured. A reactant concentration study, where we varied the volume of citrate solution, led to the development of a new method for synthesising 25 nm AuNPs demonstrating monodispersity ( Figure 2) and better reproducibility (Table 1) . For both the old method (Turkevich-Frens) and our revised method, the concentration (% w/v) of the gold salt and citrate solutions remain the same, however, using a 2.7-fold increase in the volume of citrate solution,
we reproducibly synthesise spherical, monodispersed 25 nm AuNPs. 26, 27 In synthesising the larger AuNPs, it was noted that when the gold salt was not stored in a desiccator, there was significant variation in the size of the nanoparticles produced.
This effect was also observed when water loss from the reaction vessel was not minimised, hence affecting the reactant concentration and altering the size of the AuNPs produced. Therefore, when synthesising 55 and 90 nm AuNPs, it is important to use an anhydrous gold salt and control water loss through evaporation.
Attachment of the active component of cisplatin, cis-{Pt(NH 3 )} 2+ , to the AuNPs is facilitated through a polyethylene glycol (PEG) monolayer. PEG-based linkers are extensively used in the functionalisation of AuNPs as they are stable, non-toxic, reduce non-specific binding to proteins and possess good water solubility. 28 A large number of PEG linkers can be accommodated due to the high surface area of gold nanoparticles, 29, 30 and in addition to improving stability, circulation time, and cellular uptake, they provide an attachment site for drugs and/or cancer targeting groups. [28] [29] [30] [31] It has been shown that linkers with multi-thiol anchors, compared with their monothiol analogues, show enhanced stability when treated with small molecule reducing/displacement agents such as dithiothreitol (DTT). 31 PEGylation of the AuNPs in this study was accomplished by agitating the linker with nanoparticles at appropriate concentrations, as determined by UV-visible spectroscopy and sizedependent extinction coefficients, overnight. Experimental parameters for each size of gold nanoparticle are given (Table 2 ). The final stage in the assembly of the drug-nanoparticle conjugates was the coupling of the platinum drug to the PEGylated AuNPs. To facilitate this, cisplatin was first aquated to replace the chloride ligands with the more labile leaving group, water.
The concentration of drug used in this step was directly adapted from our previous study, 16 however, for many early batches we found that the nanoparticles turned a blue-purple colour upon addition of platinum, measured as a red of λ max of the AuNPs or shoulders/additional peaks in the UV-visible spectra (supplementary information). This is indicative of AuNP aggregation, 33 and in some cases aggregates precipitated out of solution and could not be resuspended. We believe this is a result of the decreased surface charge on the nanoparticles as they go from negatively charged (from the carboxylate groups on the PEG linker) to neutral. To eliminate this problem and determine maximum platinum loading, concentration studies were performed for each of the three different sized nanoparticles, using zeta potential as the measure of stability ( Figure 3 ). The results confirmed our hypothesis; with higher concentrations of platinum, a red shift of λ max was observed (data not shown), corresponding with the overall AuNP charge approaching zero. A linear relationship exists between the concentration of cis-{Pt(NH 3 )} 2+ added and zeta potential, a common measurement used to indicate stability, 34, 35 and is dependent upon nanoparticle size ( Figure 3 ). 
Nanoparticle Characterisation
The different sized naked, PEGylated and drug-conjugated nanoparticles were analysed using a number of techniques to measure particle size, including: UVvisible spectrometry, atomic force microscopy (AFM) and DLS. UV-visible spectroscopy shows a red shift with increasing particle diameter with a λ max around 518 nm for the 25 nm AuNPs, which is characteristic of gold nanoparticles around this size (Figure 4 ). 36 The 55 and 90 nm AuNPs have a λ max around 528 and 563 nm, respectively.
To determine the particle size, the nanoparticles were analysed in the solid state using AFM ( Figure 5 ). The effect of PEGylation and drug conjugation on particle size was also determined be used to determine the thickness of the PEG layer; 37 however any polydispersity in the size distribution makes this difficult. 38 The larger hydrodynamic diameters yielded by DLS for the latter two stages of assembly, compared to those observed for the naked AuNPs, are due to the interactions between the solvent and the covalently surface-bound PEG. This effect has been previously observed for PEGylated AuNPs, 39, 40 where hydrodynamic interactions are increased for large PEG linkers. 41 The polymer monolayer is decreasing the mobility of the nanoparticle, 42 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Determination of platinum content
The presence of platinum was confirmed by UV-visible spectrometry as spectra obtained were of a similar profile to previous studies of cisplatin in water, with a weak absorption band which can extend to 350 nm and a sharp increase in absorbance between 230 and 250 nm ( Figure 6 ). 43 To quantitatively determine the number of platinum molecules per nanoparticle, the drug-nanoparticle conjugates were first digested using sodium cyanide, 44 and subsequently analysed by inductively coupled plasma mass spectrometry (ICP-MS). We have previously been able to demonstrate drug loading of up to 300 platinums per AuNP, 16 with another study showing up to 2,812 platinums per AuNP. 20 In this study, the drug loading was found to increase significantly with increasing One issue, however, that must be resolved is the variability of the drug loading on the nanoparticles: 25 nm, 13%; 55 nm, 6%; and 90 nm, 29%. 
Nanoparticle Stability
Nanoparticle instability may manifest as agglomeration and/or particle growth, both of which result in an increase in the diameter and a red shift of λ max in the case of gold nanoparticles. Maintaining stability over time is essential for the efficacy and safety of AuNP-based drugs, as unstable nanosuspensions can affect administration and the dose delivered. 45 A previous study which investigated the stability of 20 nm AuNPs synthesised via the Turkevich-Frens method, highlighted that nanoparticle growth and precipitation from solution is an issue. 46 When stored at room temperature, the nanoparticles grew up to 6.5-fold in size and at 4 ºC, although growth was less than when stored at higher temperature, the size of the nanoparticles increased to 40 nm. 46 It was therefore of interest to study the stability of our AuNPs. We have used DLS to monitor changes in the hydrodynamic diameter of the nanoparticles over time, at room temperature and 4 ºC. We have examined naked and PEGylated nanoparticles and, for the first time, looked at the stability of platinum conjugated AuNPs.
Compared with the previous study, 46 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 they should be stored at 4 ºC. The minimised growth at this temperature is postulated to be because at the higher temperature, there is more kinetic energy to encourage agglomeration, which results in larger particle sizes. 46 As minimised growth was observed at 4 ºC for the 25 nm AuNPs, it was this temperature at which the stability of 55 and 90 nm AuNPs was examined. For either size, minimal growth is observed, regardless of whether the nanoparticles are naked, PEGylated or drug-conjugated (not shown). For the naked nanoparticles, the variation in average diameter after 28 days was 3.3 and 3.6%, for the 55 and 90 nm AuNPs, respectively. The results from the three different sized AuNPs show that the drug-conjugated nanoparticles exhibit enhanced stability compared with the previous two stages of assembly.
We also examined changes in UV-visible absorbance of the 25 nm AuNPs. This technique was used to assess AuNP stability as decreases in λ max may have indicated that aggregation had occurred and/or the nanoparticles had precipitated.
There were no drastic changes in absorbance, except for the PEGylated nanoparticles when stored at room temperature ( Figure 7 ). The drop in concentration of the PEGylated AuNPs reinforces our earlier conclusion that gold nanoparticles should be stored at low temperatures.
This investigation has established that the method we have developed for AuNP synthesis produces naked nanoparticles which are relatively stable over time. We have also demonstrated that when stored at low temperatures, 25-, 55-and 90 nmnaked, PEGylated and drug-conjugated AuNPs exhibit a smaller degree of size variation over time. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Methods Materials. All chemicals and solvents used were purchased from Sigma-Aldrich. All aqueous solutions were prepared using water filtered by a Millipore purification unit.
The synthesis of aquated cisplatin followed a published method, 47 as did the synthesis of the polyethylene glycol (PEG) linker. 16 Inductively coupled plasma -mass spectrometry. Before analysis, gold nanoparticles were digested into gold ions using a standard method of dissolution with sodium cyanide. 44 An Agilent 7700X instrument, with a micromist nebuliser and an octapole collision cell, was calibrated using solutions prepared from a Spex
CertPrep platinum standard at concentrations ranging from 0 -1000 ppb, containing 2% nitric acid. The platinum drug concentration on the AuNPs was determined using 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Ultraviolet-visible spectroscopy. UV-visible spectra were obtained using a Varian
Cary 50 Bio spectrophotometer running Cary WinUV scan software. Each sample (2 mL) was prepared at appropriate dilutions to achieve absorption values between 0 -1. Samples were examined in a silica cuvette (1 cm) and an average of three measurements was used.
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